SMARCA4/2 Inhibitor for Advanced Lung Cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (FHD-286) for a specific type of advanced lung cancer called small cell lung cancer (SCLC) that has grown back after prior chemotherapy. The drug targets cancer cells that have a specific protein marker called POU2F3.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced small cell lung cancer (SCLC) that has come back or grown after prior platinum-based chemotherapy
- Your cancer cells must show high POU2F3 protein expression (>50%) on a special test (IHC staining)
- You are generally healthy enough for treatment, with good organ and blood function
- You have not had prior treatment with similar SMARCA4/2 inhibitor drugs
- You can swallow pills and are willing to use contraception for 90 days after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (QL1706) combined with standard chemotherapy for people with advanced lung cancer that has a specific genetic change (loss of the SMARCA4 gene). The goal is to see if this combination works better than chemo alone.
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
This trial tests combining anlotinib (a targeted drug that blocks tumor blood vessels) with standard chemotherapy for a rare type of advanced lung cancer that lacks the SMARCA4 gene. The goal is to see if this combination helps people who haven't had treatment before.
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
This study tests a new drug called MHB036C combined with other anti-tumor treatments for people with advanced lung cancer or other solid tumors that have not responded to standard therapies. It aims to find a safe and effective dose and see if the combination can shrink tumors.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.